GlassScriptPhysician profile
Joshua H Wolf
NPI 1982633780
$5,299.02
in general payments reported to CMS, 2019-2025
35 companies · $2,507 in 2025
The $2,507 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $88.78 · 2021: $70.28 · 2022: $350 · 2023: $912 · 2024: $1,067 · 2025: $2,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,701 · Travel and Lodging: $658 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,701.04 |
| Travel and Lodging | $657.81 |
| Education | $126.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $1,139.17 | 2025 | Renal - Acute, Renal - Prismalung |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $909.66 | 2019-2025 | Xifaxan, Plenvu |
| Mallinckrodt Hospital Products INC. | $487.75 | 2022-2025 | Terlivaz, Acthar |
| Madrigal Pharmaceuticals | $328.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $317.33 | 2024-2025 | Iqirvo, Bylvay |
| Veloxis Pharmaceuticals, INC. | $312.59 | 2019-2025 | Envarsus |
| Intercept Pharmaceuticals, INC. | $312.04 | 2022-2025 | Ocaliva |
| Abbvie INC. | $153.53 | 2019-2025 | Mavyret |
| Alexion Pharmaceuticals, INC. | $147.28 | 2019-2025 | Ultomiris |
| Azurity Pharmaceuticals, INC. | $109.07 | 2025 | |
| Astellas Pharma US INC | $100.23 | 2022-2023 | Cresemba |
| Novartis Pharmaceuticals Corporation | $99.50 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $89.28 | 2023-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $75.99 | 2025 | Purified Cortrophin Gel |
| Invivyd INC | $73.01 | 2025 | Pemgarda |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $59.95 | 2020-2024 | Renal - Acute |
| Orphalan INC | $56.13 | 2023-2025 | Cuvrior |
| Travere Therapeutics, INC. | $54.53 | 2023-2025 | Filspari |
| Sanofi-Aventis U.S. LLC | $46.36 | 2021-2024 | |
| Sirtex Medical INC | $46.15 | 2025 | Sir-Spheres Microspheres |
| Novo Nordisk INC | $45.41 | 2025 | Wegovy |
| Vifor Pharma, INC. | $44.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $44.44 | 2020-2025 | |
| Ferring Pharmaceuticals INC. | $37.77 | 2025 | Rebyota |
| Pfizer INC. | $37.08 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $20.98 | 2022 | |
| Genzyme Corporation | $20.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.24 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.22 | 2023 | Onpattro |
| Dynavax Technologies Corporation | $19.21 | 2023 | Heplisav-B |
| Ethicon US, LLC | $18.86 | 2025 | Echelon Flex |
| Amgen INC. | $16.98 | 2024 | |
| Conmed Corporation | $14.89 | 2024 | Airseal |
| Mallinckrodt Enterprises LLC | $14.42 | 2019 | |
| Lemaitre Vascular, INC. | $7.88 | 2023 | Anastoclip Gc 8cm (Medium) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.